Stem-cell mobilization for autografting in chronic myeloid leukemia

Blood Reviews

Volumn 11, Issue 3, 1997, Pages 154-159

  Carella, A M ^a   Celesti, L ^a   Lerma, E ^a   Dejana, A ^a   Frassoni, F ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN;

ADULT; AUTOGRAFT; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; FEMALE; HUMAN; MALE; PERIPHERAL BLOOD STEM CELL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0030694645     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(97)90010-2     Document Type: Article

References (41)

1. Allan NC, Richards SM, Shepherd PCA. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic meyloid leukemia: improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392-1397.
2. Hehlmann R, Heimpel H, Hasford H et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia (CML). Blood 1994; 84: 4064-4077.
3. Talpaz M, Kantarjian H, Kurzrock R et al. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 1991; 114: 532-538.
4. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820-825.
5. Gordon MY, Godman JM. Cellular and molecular mechanisms in chronic myelogenous leukaemia: biology and therapy. Br J Haematol 1996; 95: 10-20.
6. Ozer H, George SL, Schiffer CA et al. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583. Blood 1993; 82: 2975-2984.
7. Cunningham I, Gee T, Dowling M et al. Results of treatment of Ph-positive chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol). Blood 1979; 53: 375-395.
8. Goto T, Nishikori M, Arlin Z et al. Growth characteristics of leukemic and normal hematopoietic cells in Ph-positive chronic myelogenous leukemia and effects of intensive treatment. Blood 1982; 59: 793-808.
9. Sharp JC, Joyner MV, Wayne AW et al. Karyotypic conversion in Ph'-positive chronic myeloid leukaemia with combination chemotherapy. Lancet
10. Smaller RV, Vogel J, Huguley CMJr et al. Chronic granulocytic leukemia: cytogenetic conversion of the bone marrow with cycle-specific chemotherapy. Blood 1977; 50: 107-113.
11. Carella AM, Gaozza E, Raffo MR et al. Therapy of acute phase chronic myelogenous leukemia with intensive chemotherapy, blood cell autotransplant and cyclosporine A. Leukemia 1991; 5: 517-521.
12. Carella AM, Podestà M, Frassoni F et al. Collection of 'normal' blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia. Bone Marrow Transplant 1993; 12: 267-271.
13. Kantarjian HM, Talpaz M, Hester J et al. Collection of peripheral blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive chemotherapy. J Clin Oncol 1995; 13: 553-559.
14. Korbling M, Burke P, Braine H et al. Successful engraftment of blood derived normal hemopoietic stem cells in chronic myelogenous leukemia. Exp Hematol 1981; 9: 684-690.
15. Ferraris AM, Canepa L, Melani C et al. Clonal B lymphocytes lack bcr rearrangement in Ph-positive chronic myelogenous leukaemia. Br J Haematol 1989; 73: 48-50.
16. Fialkow PJ, Martin PJ, Najfeld V et al. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood 1981; 58: 158-163.
17. Lisker R, Casas L, Mutchinick O et al. Late-appearing Philadelphia chromosome in two patients with chronic myelogenous leukemia. Blood 1980; 56: 812-814.
18. Raskind WH, Ferraris AM, Najfeld V et al. Further evidence for the existence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia. Leukemia 1993; 7: 1163-1167.
19. Sessarego M, Fugazza G, Frassoni F et al. Cytogenetic analysis of hemopoietic peripheral blood cells collected by leukapheresis after intensive chemotherapy in advanced phase Philadelphia-positive chronic myelogenous leukemia. Leukemia 1992;6:715-719.
20. Coulombel L, Kalousek DK, Eaves CJ et al. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 1983; 306: 1493-1498.
21. Barnett MJ, Eaves CJ, Phillips GL et al. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood 1994; 84: 724-732.
22. Verfaillie CM, Miller WJ, Boylan K et al. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 1992; 79: 1003-1010.
23. Becker M, Fabrega S, Belloc F et al. Interferon gamma is effective for BM purging in a patient with CML. Bone Marrow Transplant 1993; 12: 155-158.
24. Carlo Stella C, Mangoni L, Almici C et al. Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. Bone Marrow Transplant 1994; 14: 425-432.
25. McGlave PB, Arthur D, Miller WJ et al. Autologous transplantation for CML using marrow treated ex vivo with recombinant human interferon gamma. Bone Marrow Transplant 1990; 6: 115-120.
26. De Fabritiis P, Amadori S, Petti MC et al. In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation. Leukemia 1995; 9: 662-664.
27. Gewirtz A. Treatment of CML with c-myb antisense oligodeoxynucleotides. Bone Marrow Transplant 1994; 14 (suppl. 3): 557.
28. Luger SM, Ratajczak MZ, Stadtmauer EA et al. Autografting for chronic myeloid leukemia (CML) with C-MYB antisense oligodeoxynucleotide purged bone marrow: a preliminary report. Blood 1994; 84 (suppl. 1): 151a (abstr.).
29. O'Brien SG, Rule SA, Ratajczak MZ et al. Autografting for CML using bone marrow purged with MYB antisense oligonucleotide. Br J Haematol 1995; 89 (suppl. 1): 12 (abstr.).
30. Kiehntopf M, Esquivel EL, Brach MA et al. Clinical applications of ribozymes. Lancet 1995; 345: 1027-1031.
31. Leopold LH, Shore SK, Newkirk TA et al. Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias. Blood 1995; 85: 2162-2170.
32. Pachuk CJ, Yoon K, Moelling K et al. Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to non-contiguous sequences. Nucleic Acids Res 1994; 22: 301-307.
33. Carella AM, Pollicardo N, Pungolino E et al. High-dose ehemoradiotherapy followed by autologous Philadelphia-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia. Bone Marrow Transplant 1996: 17: 201-206.
34. Carella AM, Benvenuto F, Podestà M et al. Mobilization and transplantation of Philadelphia-negative peripheral blood progenitor cells early in chronic myelogenous leukemia. J Clin Oncol 1997; 15: 1575-1582.
35. Simonsson B, Oberg G, Killander A et al. Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenous leukemia (CML). Bone Marrow Transplant 1994; 14(suppl. 3): S55-S56.
36. 1-negative PBPC in CML. Br J Haematol 1996; 95: 213-214.
37. Mahon FX, Montastruc M, Faberes C et al. Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant Interferon alpha (letter). Blood 1994; 84: 3592-3594.
38. Bergamaschi G, Podestà M, Frassoni F et al. Restoration of normal polyclonal hemopoiesis in patients with chronic myeloid leukemia autografted with Ph1-negative peripheral stem cells. Br J Haematol 1994; 87: 867.
39. Podestà M, Piaggio G, Frassoni F et al. Very primitive hemopoietic cells (LTC-IC) are present in Philadelphia negative cytaphereses collected during early recovery after chemotherapy for chronic myelogenous leukemia. Bone Marrow Transplant 1995; 16: 549-555.
40. Carella AM, Frassoni F, Pollicardo N et al. Philadelphia-chromosome-negative peripheral blood stem cells can be mobilized in the early phase of recovery after a myelosuppressive chemotherapy in Philadelphia-chromosome-positive acute lymphoblastic leukaemia. Br J Haematol 1995; 89: 535-538.
41. Carella AM, Dejana A, Lerma E et al. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Br J Haematol 1996; 95: 127-130.